Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODYSSEY HoFH: Alirocumab in Homozygous Familial Hypercholesterolemia
NCT03156621Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2017
- Primary completion
- Sep 2019
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in homozygous familial hypercholesterolemia (HoFH) comparing Alirocumab SC Q2W with Placebo SC Q2W (2 arms). Primary endpoint: Percent Change in Low-density Lipoprotein Cholesterol From Baseline at 12 weeks. Started Oct 2017; status: completed.
02
Drugs
alirocumab
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NCT03156621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03156621.